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Lung cancer is the leading cause of cancer-related deaths worldwide. Although treatment methods in surgery, irradiation, and
chemotherapy have improved, prognosis remains unsatisfactory and developing new therapeutic strategies is still an urgent
demand. Immunotherapy is a novel therapeutic approach wherein activated immune cells can speciﬁcally kill tumor cells by
recognition of tumor-associated antigens without damage to normal cells. Several lung cancer vaccines have demonstrated
prolonged survival time in phase II and phase III trials, and several clinical trials are under investigation. However, many clinical
trials involving cancer vaccination with deﬁned tumor antigens work in only a small number of patients. Cancer immunotherapy
is not completely eﬀective in eradicating tumor cells because tumor cells escape from host immune scrutiny. Understanding of
the mechanism of immune evasion regulated by tumor cells is required for the development of more eﬀective immunotherapeutic
approaches against lung cancer. This paper discusses the identiﬁcation of tumor antigens in lung cancer, tumor immune escape
mechanisms, and clinical vaccine trials in lung cancer.
1.Introduction
Lung cancer is the most common cause of cancer death
worldwide in both men and women, accounting for 1.2
million deaths per year. Despite recent advances in surgery,
irradiation, and chemotherapy, the prognosis is poor [1–3].
Therefore, the development of new therapeutic strategies is
essential. Immunotherapy is an attractive candidate because
the generation of speciﬁc antitumor immune responses
through the identiﬁcation of tumor-speciﬁc antigens can
promote tumor cell death with minimal impact on normal
tissue [4]. However, immunotherapy is eﬀective in only a
limited subset of patients. Tumor escape mechanisms from
host immune surveillance remain a major obstacle, and
many tumor cells, including lung cancer, are able to promote
immune tolerance and escape host immune surveillance,
resulting in the inhibition of anti-tumor immunity [5, 6].
These include a decrease or loss of the expression of tumor
antigen, downregulation or loss of expression of human
leukocyte antigen (HLA) molecules, expression of immuno-
suppressive factors by cancer cells, regulatory T cells, and
tolerant dendritic cells. Understanding of the immune-
evasion mechanisms regulated by tumor cells is necessary in
developingmoreeﬀectiveimmunotherapeuticapproachesto
lung cancer.
2. Immune Recognition of Cancer
Tumor regression in vivo is mediated by innate and
adaptive immune responses involved with tumor-antigen
presentation in the patient’s lymphoid tissues. Innate
mechanisms trigger inﬂammatory responses in the tumor
microenvironment that presents suﬃcient local cytokines
(i.e., IL-2, IL-12, IL-18, and IL-23) and stimulates antigen
presenting cells (APCs) and dendritic cells (DCs) against
tumor antigens [7, 8]. After DCs capture and digest tumor
cells, tumor antigens associated with human leukocyte
antigens (HLA I or HLA II) on the DC surface are presented
to T-cell receptors (TCRs) of naive CD4+ and CD8+ T cells,
resulting in the activation of naive T cells. Subsequently,
costimulatory molecules (CD80, CD86) on DCs interact
with CD28 on T cells for the full activation of T cells. After2 Journal of Biomedicine and Biotechnology
activation and costimulation, CD4+ and CD8+ cells both
produce a series of cytokines that diﬀerentiate T-Helper
(CD4+) lymphocytes into two subpopulations: Th 1 and
Th 2 cells [9–11]. Th 1 cells produce IL-2, IFN-γ,T N F - α,
and granulocyte macrophage colony stimulating factor
(GM-CSF) that increase the activation of macrophages and
upregulation of HLA I molecules on the surfaces of CD8+
cells. Th 2 cells secrete IL-4, IL-5, IL-6, and IL-10 that induce
naive B cells to produce speciﬁc antibodies.
The shifting towards Th2 pattern has recently been
associated with increased tumor metastasis and decreased
survival in many human and animal neoplasia. IL-4, IL-6
and IL-10 levels, but not IFN-γ and IL-2, were signiﬁcantly
higher in the serum, secreting supernatant or transcripts
produced by PBMCs from lung cancer patients [12, 13].
IL-6 and IL-10 secretion derived from lung cancer cells is
upregulated by tumor cell-derived prostaglandins and TGF-
β. IL-6 induces directly STAT3 signaling of cancer cells to
upregulate several genes, such as c-myc, bcl-2 and Mcl-
1, resulting in induction of tumorigenesis [14]. IL-10 also
possesses several properties that suppress the generation of
anti-tumor immunity [12, 13]. IL-10 inhibits a broad array
of immune parameters, including proinﬂammatory cytokine
production by macrophages, antigen-presentation function,
T lymphocyte proliferation, and Th1 cytokine production.
Increased IL-4 by tumor cells repressed the secretion of Th1
cytokines has been found to have inhibitory eﬀects on anti-
tumor immune response. IL-4 directs the development of
Th2 cells and downregulates IFN-γ production in Th1 cells,
inhibits the production of IL-12 and IFN-γ by monocytes
[12, 13]. Therefore IL-4 and IL-10 are key cytokines for the
inhibition of Th1 cytokine response and the development
of the Th2 cytokine response, which reduces the protective
cellular immunity and induces tumor progression.
Cytotoxic T cell (CTL) is a major eﬀector of tumor
regression. When CD8+ T cells bind to class I antigens on
APCs, Th1 cytokines stimulate the generation of antigen-
speciﬁc CTL, which expresses perforins, granzyme, and Fas
ligand that directly eliminate neoplastic cells. CTLs also
secrete speciﬁc cytokines (IFN-γ,T N F - α,a n dT N F - β)a n d
activatemacrophagesagainsttumorcellsdirectly[10,11,15].
Conversely, depending on the tumor microenvironment,
these cytokines also stimulate tumor progression [16].
Natural killer (NK) and Natural Killer T (NKT) cells
are innate immune cells critical for the ﬁrst line of defense
against tumorigenesis [17]. Diﬀerent from T cells, NKs and
NKT cells inhibit tumor growth in an MHC-nonrestricted
manner [18–23]. Natural Killer (NK) cells are a type of
cytotoxic lymphocyte that exhibit cytolytic activity against
a variety of allogeneic targets in a nonspeciﬁc, contact-
dependent, nonphagocytic process which does not require
prior sensitization to an antigen [18–20]. NK cells share
several properties with conventional cytotoxic T cells (CTL)
and appear to possess similar mechanisms for cytolysis
including secretion of perforin and granzyme. Their cyto-
toxic activity is positively regulated by IL-2 and IFN-r.
Frequently, tumor cells (like stressed cells) express diﬀerent
glycoproteins (MICA and MICB) on their surfaces that
function as ligands for NKG2D receptors on NK cells.
Once activated, these receptors stimulate NK cell activity
to lyse tumours through the perforin/granzyme pathway or
apoptosis-inducing ligands such as tumour-necrosis factor
(TNF-) related apoptosis-inducing ligand (TRAIL or FasL).
NK cells secrete IFN-γ by IL-12, which inhibits tumour-
cell proliferation, enhances tumour-cell apoptosis, improves
tumour antigen presentation and inhibits angiogenesis
[18–21].
NKT cells are a subset of T cells that coexpress an
αβ T-cell receptor (TCR), but also express a variety of
molecular markers that are typically associated with NK
cells, such as NK1.1 [22–24]. NKT cells are restricted by
the nonpolymorphic CD1d molecule and are activated by
lipid and glycolipid antigens presented by CD1d. NKT
cells share other features with NK cells as well, such as
CD16 and CD56 expression as well as cytolytic perforin
and granzyme release. Although NKT cells possess NK-like
cytolytic activity, their activation results in rapid production
of IFN-γ and expression of CD40L, thus providing help
for activation of CD40-expressing APCs and generation
of cellular and humoral immune responses [17, 22–24].
Under the existence of tumor cells, NKTs cell recognition
of glycolipid antigens of tumor cells presented by CD1d can
either lyse tumour cells directly using the perforin/granzyme
system or ligands (TRAIL or FasL) for death receptors or
stimulate other cytotoxic cells such as NK and CD8+ T
cells through IFN-γ secretion [22–24]. NK and NKT cells
both produce chemokines that are important for recruiting
eﬀector T cells, B cells, neutrophils, and other NK and NKT
cells to the disease site. NK- and NKT-derived IFN-r by
stimulation of IL-12 is able to up-regulate the expression of
the chemokine receptor CXCR3, which mediates subsequent
recruitment of CXCR3+ T and NK cells to tumor-inﬁltrated
tissues [17, 22–24].
3.Vaccine Strategies
The capture and presentation of tumor antigen by APCs
are key steps for successful active immunotherapy [25, 26].
In comparison to restriction of class I or class II pathways
and selective stimulation of either CD4+ Th cell or CD8+
cytotoxic T-cell eﬀectors by peptides, whole recombinant
proteins are processed into multiple peptides and presented
by APCs via class I and class II pathways to CD4+ and
CD8+ T cells, respectively, and have the potential for
generating immune eﬀectors and immune memory [25].
Tumor-derived antigen mixtures contain multiple dominant
and minor antigenic determinants within whole proteins,
permitting the host to select, process, and present on HLA,
the most immunogenic epitopes relative to that individual
[25].
The most commonly used multivalent formulations
employ autologous or allogeneic tumor cells. Autologous
tumor vaccine is produced by isolating adequate amounts of
tumor cells from an individual and processing these tumor
cells into a vaccine formulation in vitro; the vaccine is
then administered to the individual from whom the tumor
cells were isolated. Autologous tumor vaccines have been
shown to have immunologic activity in a number of studies.Journal of Biomedicine and Biotechnology 3
An autologous tumor vaccine usually combined with an
adjuvant elicits eﬀectively a speciﬁc CTL-mediated cytolytic
response against tumor cells [25–28].
Allogeneic tumor vaccine composed of tumor cells
isolated from the tumor of one patient, killed and processed,
and administered to another patient in order to stimulate
cytotoxic immune responses to a similar tumor cell type.
The cells found in this type of whole-cell vaccine express
many cell-surface tumor-associated antigens. This vaccine
is frequently administered with an adjuvant immunostim-
ulant. Using allogeneic antigens also generates a uniform
preparation, which speeds up the immune assessment and
comparability not oﬀered by the use of autologous tumor
antigen, thereby allogeneic approaches are attractive during
therapeutic development and clinical testing [25–28].
Twoadditionalallogeneicsourcesofantigenaresynthetic
peptide and recombinant protein. In contrast to allogeneic
tumor, peptides and proteins are applied in monovalent for-
mulations. In spite of being easily synthesized and uniform,
providing the simplest and most reproducible immunologic
measures of biological eﬃcacy, peptides require patient
selection based on HLA tissue typing and also have desig-
nated restriction to class I or class II pathways, selectively
stimulating either CD8+ cytotoxic T-cell eﬀectors or CD4+
Thcells,responsibleforimmunememory.Bycontrast,whole
recombinant proteins are processed into multiple peptides
and presented by APCs via class I and class II pathways to
CD4+ and CD8+ T cells, respectively, and have the potential
for generating responses of immune eﬀectors and immune
memory [25–28].
By identiﬁcation of tumor-associated antigens, many
tumor vaccines have been established by investigators and
eﬀective generate speciﬁc immunity against tumor cells
and treatment in lung cancer patients. Cancer-associated
mucins are a potential target for immunotherapy. These
molecules facilitate adhesion of malignant cells to the
endothelial cell surface and promote metastases. They are
tumor-speciﬁc immunogens because they exhibit unique
glycosylation patterns [29]. The BLP25 liposome vaccine
(L-BLP-25) carries the mucin-1 (MUC-1) protein admixed
with monophosphoryl lipid A as an immune adjuvant.
Trials of the L-BLP-25 vaccine in stage III and IV NSCLC
patients have demonstrated safety but not a statistically
signiﬁcant survival beneﬁt. Nonetheless, a subset of patients
(n = 75) with IIIB disease has shown a trend towards
improved survival (P = .09). In 2007, Merck Serono spon-
sored a multicenter (international) phase III, randomized,
double-blind, placebo-controlled trial where 1300 patients
with unresectable stage III NSCLC responded to ﬁrst-line,
platinum-based chemoradiotherapy [30].
The C-T antigens (MAGE-1, MAGE-3, BAGE, BAGE,
GAGE, KK-LC-1, and NY-ESO-1) are encoded by genes
that are completely silent in most normal tissues but are
activated in a wide variety of tumors. Although normal
cells, placental trophoblasts, and male germ-line cells express
C-T antigen, the cells lack HLA I molecules and cannot
present the antigens to T cells [31, 32]. Therefore, tumor
C-T antigens are considered to be highly promising targets
for anticancer vaccine [33]. MAGE-3 is aberrantly expressed
in a wide variety of tumors, including NSCLC. Several
CD8+ T-cell epitopes of MAGE-3 have been identiﬁed
in vitro. GlaxoSmithKline produced a vaccine that car-
ries recombinant MAGE-3 fusion protein (His-tagged/full-
length MAGE-3 protein/inﬂuenza protein D) plus immune
adjuvant AS02B (monophosphoryl lipid A and QS21) [34].
A recent randomized phase II trial conducted on 182 stage
IB or II NSCLC MAGE-3 positive patients (122 vaccine and
60 placebo) has demonstrated a trend towards improved
survivalinstageIIpatientsreceivingthevaccinecomparedto
placebo. The results are enough for a phase III investigation.
The study plans to accrue 2270 MAGE-3-positive patients
with completely resected stage IB, II, or IIIA NSCLC.
Furthermore, epitopes from the CT antigens TTK protein
kinase (TTK), lymphocyte antigen 6 complex locus K (LY6
K), and insulin-like growth factor (IGF)-II mRNA-binding
protein 3 (IMP-3) have been demonstrated to elicit CD8
responses in 20%–70% of HNSCC patients tested [35],
and 50% HNSCC (5/10) patients vaccinated against these
peptides have resulted in clinical responses [36].
Epidermal growth factor (EGF), now a well-established
target for biologic therapy, is also a potential tumor antigen.
Preclinical studies have established the antigenicity and anti-
tumor activity of EGF protein administered to animals
[37]. In two randomized phase II studies, recombinant EGF
conjugated to Neisseria meningitides P64K protein as carrier
protein and emulsiﬁed with the adjuvant Monotanide ISA51
was administered to 40 advanced NSCLC patients. Anti-
EGF antibody responses were identiﬁed with a signiﬁcant
increase in survival for patients who maintained antibody
response (9.1 months versus 4.5 months). The same agent
was tested in a larger randomized phase II clinical trial that
vaccinated 100 patients with stage IIIB or IV NSCLC who
had progressed through ﬁrst-line chemotherapy, and 45% of
vaccinated patients developed a strong anti-EGF antibody
response and decreased serum EGF concentration. Com-
pared to controls (best supportive care), those who received
the treatment had signiﬁcantly longer overall survival (8.5
versus 4.3 months) [38, 39].
Xenogeneic anti-idiotype antibodies are quite unique
antigen-mimic preparations, generated as antibodies to
tumor antigen-binding sites on other antibodies (that gen-
erates a template of the antigen). The xenogeneic nature
of these preparations makes them inherently immunogenic,
and the similarity of the antiidiotype antibody to the tumor
antigen allows cross recognition of the parent/native protein.
Antiidiotypic vaccines are used to elicit tumor-speciﬁc
antibodies as the dominant eﬀectors for therapeutic activity;
these have been the most widely tested immunotherapy
approaches in SCLC [25–28].
Tumor antigens like the ganglioside, GD-3, have been
identiﬁed as targeted active immunotherapy strategies
become more feasible. In SCLC patients after chemotherapy
or combined chemotherapy and radiotherapy, vaccination
with an anti-idiotype GD3 monoclonal antibody (BEC2)
and BCG induces antiganglioside GD3 antibodies and
prolong survival compared to control subjects. However, this
a g e n tp r o v i d e sn os u r v i v a lb e n e ﬁ ti nal a r g er a n d o m i z e d
international phase III trial by Merck. BEC plus BCG vaccine4 Journal of Biomedicine and Biotechnology
induces humoral response in only one-third of 213 patients
and the investigators suggest that a multivalent rather than a
monovalent approach may be better in the treatment of lung
cancer patients [40].
Other tumor-associated antigens, hyaluronic acid-med-
iated motility (RHAMM) and carboanhydrase IX (G250/
C A IX ),ar eo v e r e x p r es s edi nH N SC Can ds e rv edasi m m un o -
gens in vivo in 4 of 8 HLA-A2+ patients, while 0.06%–0.13%
ofCD8+ eﬀectorTcellsrecognizedtetramersforRHAMMor
G 2 5 0a n ds e c r e t e dI F N - ra n dg r a n z ym eBi nE L I S P O Ta s s a y s
[41]. Otherwise, NKG2D ligands MHC class I-related chain
molecules A (MICA) and UL16-binding proteins (ULBPs)
are over-expressed in the primary HNSCC as compared
to nontumor tissues of vocal cord polyps. The ligands
reportedly activate NK cells and generate adaptive immunity
through binding to NKG2D receptor. However, other studies
demonstrate signiﬁcant variability of expression [42, 43].
4. Promotion of Antigen Recognition
In order to initiate or promote antigen-speciﬁc responses,
tumor antigens have to incorporate adjuvants that lead to
increases in various arms of the immune cascade, antigen
recognition, uptake, presentation, and/or antigen-speciﬁc
cellular reactivity [25, 26]. Some biologic adjuvants [25, 26,
44](bacillusCalmette-Guerin(BCG),diphtheriatoxoid,and
tetanus toxoid and chemical adjuvants (aluminum hydrox-
ide, montanide ISA 51, and incomplete Freund’s adjuvant)
induce an inﬂammatory response at the site of delivery,
whichacceleratesthemigrationofAPCstothesiteofdelivery
and enhance the capture and processing of tumor antigens
by APCs in the inﬂammatory environment. Moreover, DC
precursors are harvested from patients and cultured with
antigen to activate DCs ex vitro [45] .T h ea c t i v a t eD C sa r e
subsequently delivered back to the individual, where they
expectedly migrate to the lymph node and come to the
desired antigen-speciﬁc immune response.
Small molecules like Toll-like receptor-9 (TLR9) agonists
[46, 47] can stimulate Toll-like receptors and initiate the
innate and adaptive immune responses and have been
under investigation for treating cancer. TLR9 is expressed
in endosomes of dendritic cells, plasmocytoid dendritic
cells, and T and B lymphocytes and regulates innate
antigen-speciﬁc immunity via the recognition of pathogen-
associated molecular pattern. Activation of TLR9 signalling
pathway by TLR9 agonists leads to increased production
of proinﬂammatory cytokines and chemokines and stim-
ulation of an immune response with antitumor eﬀects.
Several new immunomodulatory oligonucleotides have been
evaluated in models of human cancer [46, 47]. Among
these, PF-3512676 (ProMune) is particularly promising. It
contains unmethylated cytosine and guanine (CpG) motifs
and a nuclease-resistant phosphorothioate backbone. The
anticancer activity of PF-3512676 is related to direct and
indirect immunomodulation of both innate and adaptive
immune responses. Plasmocytoid dendritic cells stimulated
by PF-3512676 express increased levels of MHC I and II
and costimulatory molecules (leading to improved antigen
presentation)secretecytokinesandchemokinesthatenhance
natural killer (NK) cell activity directed toward tumor
cells, present tumor-speciﬁc antigens and costimulatory
molecules to B and T cells and generate long-living antigen
speciﬁc cytotoxic T-lymphocytes, and antibody responses.
A good indicator of activation and maturation of dendritic
cells by PF-3512676 is the production of IFN-α and the
subsequent induction of interferon-inducible protein 10 (IP-
10), an antiangiogenic cytokine [46]. In NSCLC, a phase II
study enrolling 112 chemonaive patients with NSCLC was
conducted. The patients received PF3512676 in combination
with platinum, and taxane doublet chemotherapy. Twenty-
eight (37%) patients had a partial or complete response
with the combination of chemotherapy and PF-3512676
and 7 (19%) with chemotherapy alone. Based on these
preliminary data, two phase III trials were conducted to test
the eﬃcacy of PF-3512676 in combination with platinum
based chemotherapy in advanced NSCLC patients [46, 47].
Cytokine can be used at the site of tumor or combined
with exogenous tumor antigen to promote APC maturation
and activation and HLA class I molecule expression on
tumor cells, which generates eﬀective CTL responses againt
tumor cells [25, 48]. In vivo cytokine gene transfer can
also target normal cells in the tumor environment, thereby
achieving high local concentrations of cytokine that avoid
toxicities associated with systemic administration. Gene
therapy has been applied in clinical trials for over a decade.
Gene transfer of cytokines or costimulatory molecules
directly to tumor cells ex vivo and in vivo are attractive
ways of making nonimmunogenic cells more immuno-
stimulatory [25, 49]. The cytokine granulocyte-monocyte
colony stimulating factor (GM-CSF), a signiﬁcant mediator
of proliferation, maturation, and migration of dendritic
cells can enhance the generation of potent, durable anti-
tumor immunity [50, 51]. GM-CSF and IL-2 combined
with tumor antigen causes high local concentrations of
stimulatory cytokines at the site of antigen delivery and
stimulates APC and T cell activation. Fas ligand (FasL)
and GM-CSF coexpressed in tumor cells administrate in to
mice, which accelerate the recruitment of innate immune
cells, activation of dendritic cells, and the generation of
speciﬁc and memorial anti-tumor immunity against tumor
cells in vivo [52]. The beneﬁt of incorporating GM-CSF
into anti-tumor vaccines is well established. In a multi-
center phase I/II trial, Nemunaitis et al. produced a vaccine
(GVAX) that contains autologous, irradiated lung tumor
(NSCLC) cells engineered to secrete GM-CSF. Among 33
patients with advanced NSCLC, three (2 with bronchoalve-
olar carcinoma) achieved complete response and prolonged
remission. Longer median survival was observed in patients
whose vaccines secreted more GM-CSF (17 months versus 7
months), suggesting a cytokine dose-response relationship.
Eight of ten patients with early-stage lung cancer remained
disease-freewithamediumfollowupof12months.However,
establishing GVAX required much time. In the beginning,
83 tumors had to be harvested. Vaccines could not be
successfully produced in 16 patients and 11 others died
before vaccine was delivered. The medium generation time
was 49 days. There were only 43 patients immunized with
the vaccine [50, 51].Journal of Biomedicine and Biotechnology 5
Most immunomodulatory drugs, including cycloox-
ygenase-2 (COX-2) inhibitors and thalidomide-like agents
(Lenalidomide), have immunologic properties that promote
a favorable immune environment [53, 54]. Furthermore,
antisuppressive agents like cyclophosphamide and ﬂudara-
bine abrogate the activity of immunosuppressive cells-
regulatory T cells (T-reg). Therefore, these agents have
therapeutic potential that can synergize with cancer vaccines
and other active immunotherapy strategies [25, 55–60].
COX-2 is an enzyme that catalyzes the synthesis of
prostaglandins (PGs), including prostaglandin E2 (PGE2)
[61]. COX-2 and PGE2 overexpression are seen in many ma-
lignanciesincludinglungcancer.Innonsmallcelllungcancer
(NSCLC), COX-2 is overexpressed in most adenocarcinomas
and squamous cell carcinomas. Elevated tumor COX-2
and PGE2 levels have been implicated in angiogenesis,
tumor invasion, resistance to apoptosis, and suppression
of antitumor immunity. PGE2 secretion mediated by
COX-2 can negatively regulate T-lymphocyte proliferation
and cytotoxicity, and mediate the imbalance between
IL-10 and IL-12 in favor of IL-10 production. The tumor
microenvironment is predominantly polarized toward
Th2-like or immunosuppressive immune responses. The
overexpression of phosphoglycerate kinase (PGK-1) [62, 63]
or Interlukin-27 (IL-27) [64] in lung cancer cells both
downregulate COX-2 and PGE2, which not only directly
suppress tumorigenesis but also enhance the activation of
immune cells and generation of speciﬁc Th1 anti-tumor
immune response in vivo. Preclinical animal model studies
show tumor reduction when animals are treated with either
nonspeciﬁc or speciﬁc inhibitors of COX-2. Based on these
observations, celecoxib, a selective COX-2 inhibitor, has
been evaluated in combination with chemotherapy for the
management of metastatic NSCLC in patients who have
failed prior chemotherapy. Ongoing clinical trials are also
evaluating the combination of celecoxib with chemotherapy
(paclitaxel and carboplatin) and/or radiation or celecoxib in
combination with epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI; geﬁtinib) of NSCLC [53, 61].
Lenalidomide [47, 54] was synthesized based on the
structural backbone of thalidomide, by adding an amino
group at position 4 of the phthaloyl ring and removal of
the carbonyl group of the 4-amino-substituted phthaloyl
ring. Such structural changes were designed to enhance its
immunomodulatory and antitumor activity. Lenalidomide
induces increase in IL-2 and IFNγ secretion and upreg-
ulation of CD40L expression on anti-CD3-stimulated T
cells, resulting in activation of natural killer cells, and thus
improving host immunity against tumor cells. Compared
to thalidomide, lenalidomide is 50 to 2000 times more
potent in stimulating T-cell proliferation and activation and
50–100 times more potent in augmenting IL-2 and IFNγ
production. In addition, lenalidomide has been shown to
inhibit endothelial cell migration and adhesion, perhaps by
downregulating endothelial cell integrins. Lenalidomide is
reported to downregulate key cytokines such as TNF-α,I L - 6 ,
IL-8, and VEGF, that is, cytokines which favour tumor cell
survival, proliferation and possibly resistance to therapy,
m a i n l yb ya ﬀecting the tumor vasculature. In solid tumors,
lenalidomide proved to have a good safety proﬁle both
in monotherapy and in combination with chemotherapy
showing results in terms of antitumor activity in several
tumor types and also in NSCLC. In fact, Miller et al. tested
the feasibility of lenalidomide at a dose escalated from 5 to
10 to 25mg/day in 20 patients with solid tumors refractory
to standard treatment. One partial response and three
stable diseases were documented; of these patients, three
had NSCLC diagnosis. This study recommended 25mg/day,
orally,oflenalidomideassingleagentfor4weeksfollowedby
2-week rest period. Similarly, Kalmadi et al. explored safety
and tolerability of lenalidomide in association with docetaxel
and carboplatin in 14 patients with advanced solid tumors.
5. Challenges in Immunotherapy:
Tumor EscapeMechanism
By identifying tumor-speciﬁc antigens recognized by CTL,
several clinical trials of therapeutic vaccine bearing with
these antigens have promoted tumor-speciﬁc immunity.
However, only 2%–4% of patients have observed tumor
regression [65]. There is a number of escape mechanisms
from the host’s immunosurveillance regulated by cancer
cells, including loss of tumor antigen, downregulation
of HLA molecule expression, and secretion of immuno-
suppressive soluble factors ligands [65].
During tumor progression, tumor cells often display loss
or down-regulation of HLA I antigen. In surgically resected
specimens, 25%–94% of NSCLCs have down-regulated HLA
I expression. Thereafter, one possible mechanism of the
escape host immuno-surveillance immune escape is tumor
cells with abnormal HLA I antigen expression, leading to
develop clinical cancer [66]. A haplotype loss of HLA I
antigen is a common cause of abnormal HLA expression in
various types of tumors, as mentioned above [67–70]. More-
over, β2-microglobulin gene (β2-m) abnormality is common
in abnormal expressions of HLA I [67]. Transduction of
the wild-type β2-m gene renders them positive for HLA
class I expression. An autologous CTL clone is induced by
stimulating the wild-type β2m-transduced lung cancer cell
line with the genetic abnormality of β2m.H L Ac l a s sI -
deﬁcient cancer cells can escape from an attack by CTLs,
and a reformation of HLA class I expression in cancer cells
restores CTL recognition against cancer cells.
Cancer cells often secrete immuno-suppressive cytok-
ines, including transforming growth factor-β (TGF-β),
interleukin-10 (IL-10), and indoleamine 2,3-dioxygenase
(IDO) [71, 72]. IDO is a tryptophancatabolism enzyme
that is overexpressed in various tumors. It leads to T-
cell dysfunction and apoptosis through the depletion of
tryptophan. Arginase, an amino acid-catabolizing enzyme,
is expressed in tumor cells to decrease CD3z expression of
T-cell clones [73] and inhibit antigen-speciﬁc recognition.
The inﬁltrating T cells in the patients possess a high level
of arginase activity (arginase I) and decreased CD3ξ levels.
S o l u b l eM H Cc l a s sIc h a i n - r e l a t e dm o l e c u l eA( M I C A )
derived from tumor cells is able to systemically downregulate
NKG2D expression on the surface of CD8 T cells and natural
killer (NK) cells [74], thereby impairing activity of eﬀector6 Journal of Biomedicine and Biotechnology
cells against tumor cells. Thus, tumor-derived soluble factors
assist tumor cells in the evasion of immune attack, allowing
tumor progression and metastasis.
Many cancers express immuno-suppressive costimula-
tory molecules such as programmed death ligand-1 (PD-L1)
[75, 76] PD-L1 has been shown to suppress immune
responses through PD-1 receptor on activated T cells and
B cells, which decreases immune responses. PD-L1 on lung
cancer cells demonstrates that it is able to increase apoptosis
of antigen-speciﬁc T cells and to inhibit CD4 and CD8 T cell
activation, resulting in reduced anti-tumor immunity and
evasion of host immune surveillance [75, 76]. Fas system is
one of the killing pathways by CTLs and NK cells to tumor
cells in human body. However, reducing Fas expression and
the over-expression of Fas ligands are observed in lung
cancer, contributing to tumor immune privilege by inducing
FasL-mediated apoptosis of host CTL and NK cells and
destructing inﬁltrating Fas-bearing lymphocytes [77].
6. Immunosuppressive Immune Cells
(MDSC,TAM,Treg)
Solid tumorsconsist ofboth malignant cellsandanumber of
nonmalignant stromal cell types, including endothelial cells,
ﬁbroblasts, and various immune cells. Complex interactions
occur between these within the tumor microenvironment
and impact on immunosurveillence and tumor progression
[78].Ithasbeenreportedthatanti-tumorimmuneresponses
are downregulated by immuno-suppressive immune cells,
which include myeloid-derived suppressor cells (MDSCs),
M2 macrophages, and regulatory T cells (Tregs). VEGF, GM-
CSF,M-CSF,IL-6,andIL-10secretedbygrowingtumorsand
stromal cells cause abnormal myelopoiesis that ultimately
leads to the suppression of immune responses. The success
of immune therapy for cancer will depend on integrating
strategies that down-regulate immune suppression [79, 80].
Studies provide evidence that MDSCs are directly
involved in the suppression of immune responses in cancer.
An increase in the number of MDSCs has strong natural
suppressiveactivityincancerpatientsortumor-bearingmice
[81, 82]. In murine tumor models, the number of MDSCs
in spleen increase by 5- to 20-fold, depending on the tumor
model, and is easily detected in the lymph node and tumor
site. Recent ﬁndings demonstrate that ROS and peroxynitrite
derived from MDSCs can induce antigen-speciﬁc CD8+ T
cell tolerance through a posttranscription mechanism that
involves the modiﬁcation of CD8 and TCR itself on the T
cell surface [83–85]. CD8+ T cells from MDSC-treated mice
are unable to produce IFN-r and interleukin-2 in response
to speciﬁc peptides and do not kill peptide-load target
cells. MDSCs, in addition to inducing tumor-speciﬁc T-cell
tolerance, also cause the development of Tregs. MDSCs in
tumor-bearing hosts also reduce the number and activation
of T-cells through the production of nitric oxide (NO) and
arginase-1 [86, 87]. NO inhibits T cells through the blockade
of activity in the JAK3 and STAT5, inhibition of HLA II
gene expression, and induction of T cell apoptosis, while
arginase 1 causes the depletion of arginine and translational
blockade of the ξ-chain of CD3. Combination of high
arginase activity and increased NO production by MDSCs
also leads to increased ROS production. This increase is
able to suppress T cells by cell-to-cell contact. Depleting
of MDSCs by using anti-Gr1 antibodies has been shown
to signiﬁcantly improve CD8+ T cell immune response and
allow for eradication of the variant tumor cell lines [81, 82].
In addition, elimination of MDSCs with All transretinoic
acid (ATRA) has also been found to promote CD4- and
CD8-mediated tumor-speciﬁc immune responses, and may
open an opportunity to improve the eﬀect of cancer vaccine
[81, 82].
In some cases, macrophages can represent 50% of
the cellularity within a tumor. The increased number of
M2 macrophages in the tumor stroma is associated with
poor prognosis in NSCLC [88–92]. M2 macrophages are
derived from circulating monocytes that are recruited to
tumors by chemotactic factors such as CCL2, VEGF and
M-CSF [88–90]. M2 macrophages are able to secrete IL-10
and TGF-β and inhibit Th1 immune response, leading
to enhanced wound healing and tissue remodeling as
well as promotion of tumor formation. Diﬀerentiation of
M2 macrophages is induced by IL-4, IL-10, IL-13, IL-21,
activin A, immune complexes, and glucocorticoids. M2
m a c r o p h a g e sa l s oe x p r e s sh i g hl e v e l so fI L - 1r e c e p t o r
antagonist, CC ligand 22 (CCL22), scavenger, mannose
receptor, galactose receptor, arginase I, and CD163 antigen.
In tumor angiogenesis, M2 macrophages play an important
role of secreting proangiogenic factors and enzymes,
including vascular endothelial growth factor (VEGF) and
matrix metalloproteinase 9 (MMP9) [91, 92]. Several studies
have shown that the activation of TLRs, such as TLR9,
decreases the development and activity of M2 macrophage
[88–90, 93], and activation of TLR9 by synthetic CpG
oligodendronucleotides demonstrated anti-tumor eﬀects
and survival increased signiﬁcantly in many preclinical
models. Knock-down of a crucial phosphatase, SHIP1, has
been showed to suppress development of M2 macrophages
in mice, and thus, pharmacological modulators of this
phosphatase are under investigation currently [88–90, 93].
The accumulation of regulatory T cells (Tregs) in tumor
is reportedly associated with unfavorable prognosis in
NSCLC patients [94]. The number of Tregs exist in high
proportions in the TIL of patients with lung cancer and play
a role in suppressing anti-tumor immune responses. Tregs
canberecruitedtotumorsitesbysecretionofCCL22derived
from tumor cells and TAMs [95]. Tregs isolated from tumors
mediate the potent inhibition of proliferation of autologous
peripheral blood T cells stimulated by anti-CD3 or anti-
CD3/anti-CD28 [96]. These Tregs play a role in inducing or
maintaining tolerance to tumor in patients with lung cancer.
Tregs are known to suppress DC function via TGF-β and
IL-10 [97]. Recent clinical studies indicate that high levels of
tumor inﬁltration by activated CD8+ T cells combined with
a low number of Tregs is a signiﬁcant positive prognostic
f a c t o rf o rs u rvi v a li nc a n c e rp a t i e n t s[ 98, 99]. Thus, reducing
the number or activity of Tregs in tumor-bearing hosts
may induce eﬀective tumor immunity by activating tumor-
s p e c i ﬁ ca sw e l la sn o n s p e c i ﬁ ce ﬀector cells. Removal of Tregs
byanti-CD25antibodycanaugmenteﬀectorTcell-mediatedJournal of Biomedicine and Biotechnology 7
tumor immunity that strongly inhibits tumor growth in
cancer patients [100, 101]. Activation of GITR signaling by
agonist anti-GITR antibody or GITR ligand can inhibit the
suppressive activity of Tregs and enhance tumor-speciﬁc
CD4+ and CD8+ T cell responses. CTLA-4 blockade by
anti-CTLA-antibody also augments tumor inhibition by
attenuating Treg suppression and augmenting eﬀector T-cell
activity. The combination therapy of anti-CTLA-4-blocking
antibody and anti-GITR agonist antibody has demonstrated
thattherehavesynergisticantitumoreﬀectscausingrejection
of advanced stage tumors compared with either antibody
therapy alone [100, 101].
7. Conclusion
Immunotherapy for lung cancer is potentially eﬀective
treatment in terms of high speciﬁcity, low toxicity, and
prolonged activity. Nonetheless, it is necessary to integrate
novel approaches with traditional therapeutic methods to
oﬀer more appropriate therapy, including representation of
antigen epitopes, restoration of APC immune-stimulating
activity, expansion of tumor-reactive T cells, and down-
regulation of suppressor pathways. In the future, using
combinations of multiple immunologically active agents,
conventional treatment modalities, and novel targeted ther-
apies will overcome limitations of any single approach and
lead to signiﬁcant improvements in therapeutic outcomes of
lung cancer.
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